XML 40 R23.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Note 14 - Stockholders' Equity and Stock-based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Shareholders' Equity and Share-Based Payments [Text Block] | 14. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Stock-Based Compensation The Company includes stock compensation expense within general and administrative expenses in the Consolidated Statements of Operations. The Company recognized total stock-based compensation costs, net of forfeitures, of $1.2 million and $2.1 million for the years ended December 31, 2024 and 2023, respectively. Stock-based compensation expense is related to equity awards to executives and other employees, awarded from the Company's Amended and Restated long-term incentive plan. Issuance of Stock-based Awards The Company has a long-term incentive plan, originally approved by the Board of Directors in 2019. In July 2021 and in August 2023, the plan was amended (the “Amended and Restated Plan”) to increase the maximum number of shares of common stock available for issuance from its original 1,675,000 shares to 4,000,000 (in July 2021) and to 5,500,000 (in August 2023). The plan provides for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalents, substitute awards, other stock-based awards, cash awards and/or any combination of the foregoing which may be granted to employees, officers and directors of the Company and affiliates or to any other person who performs services to the Company and affiliates, including independent contractors and consultants of the Company and its subsidiaries. At December 31, 2024, the number of shares of common stock available for issuance under the Amended and Restated Plan is 2,129,805 shares. No participant may receive a grant covering more than 2,000,000 shares of our common stock in any year and a non-employee member of the Board may not be granted more than 100,000 shares in any year. In the event of certain changes in the Company’s common stock such as recapitalization, reclassification, stock split, combination or exchange of shares, stock dividends or the like, appropriate adjustment will be made in the number and kind of shares available for issuance under the Amended and Restated Plan as well as the purchase price, if any, per share. (a) Stock Appreciation Rights On June 26, 2023, the Company granted 685,437 stock appreciation rights (“SARs”) under the Amended and Restated Plan, with a $10.00 strike price. The SARs 100% vest when the closing price of the Company's common stock averages $10.00 over 10 (ten) consecutive trading days, prior to January 1, 2025. At December 31, 2024, the SARs had not met the 10 (ten) consecutive trading days requirement and expired on December 31, 2024. The SARs were valued using a Monte Carlo simulation model and expensed on a straight line basis. Upon expiration, prior amounts expensed were reversed including $11 thousand recognized for the year ended December 31, 2023. A summary of the Company's SARs activity during the fiscal year 2024 is presented in the following table:
Stock Appreciation Rights |  | Number of SARs |  |  | Weighted Average Exercise Price per Share |  |  | Weighted Average Grant Date Value per SARs |  |  | Weighted Average Remaining Contractual Term (in years) |
Outstanding at December 31, 2023 |  |  | 685,437 |  |  | $ | 10.00 |  |  | $ | 0.10 |  |  |  | 9.5 |
Granted |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Vested |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Expired |  |  | (685,437 | ) |  |  | 10.0 |  |  |  | 0.10 |  |  |  | — |
Outstanding at December 31, 2024 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
SARs vested and exercisable at December 31, 2024 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
(b) Restricted Stock Units There were no RSUs granted during the years ended December 31, 2024 and 2023. A summary of the Company's RSUs activity during the fiscal years ended December 31, 2024 and 2023 are presented in the following table:
|  | # of Restricted Stock Awards and Units |  |  | Weighted Average Grant Date Fair Value per Share |
Unvested at 12/31/2022 |  |  | 210,939 |  |  |  | 4.43 |
Vested |  |  | (183,762 | ) |  |  | 5.35 |
Unvested at 12/31/2023 |  |  | 27,177 |  |  |  | 4.11 |
Vested |  |  | (13,588 | ) |  |  | 4.11 |
Unvested at 12/31/2024 |  |  | 13,589 |  |  |  | 4.11 |
During the years ended December 31, 2024 and 2023, the Company expensed stock based compensation related to restricted stock units of $0.1 million and $0.6 million, respectively. (c) Stock Options On February 18, 2022, the Company granted executives 774,505 stock options under the 2019 plan to purchase an equal number of shares of the Company’s common stock, with a strike price equal to $6.00 per share. The stock options will vest equally over a three-year vesting period. The Company estimated the value of the options using a valuation model. The full aggregate fair value determined was $1.5 million using observable inputs from trading values of the Company's shares of stock. The stock options are expensed over the vesting period. Assumptions used in determining the valuation of the options included the following:
| • | A strike price of $6.00 with 3 year vesting terms and the closing price of the common stock of $4.11.
| • | The risk free rate assumed the average return of a U.S. Treasury bill of 3 years (the vesting period), which was approximately 0.7% at February 18, 2022.
| • | $0 dividends, as we have not historically paid dividends.
| • | A term of 6.5 years, which was determined as the midpoint between the vesting period of 3 years with an anticipated expiration date of 10 years.
| • | Volatility of approximately 44%.
A summary of the Company's stock option awards activity during the fiscal years 2024 and 2023 are presented in the following table:
|  | Number of Options |  |  | Weighted Average Exercise Price per Share |  |  | Weighted Average Grant Date Value per Option |  |  | Weighted Average Remaining Contractual Term (in years) |
Outstanding at December 31, 2022 |  |  | 2,074,505 |  |  | $ | 8.51 |  |  | $ | 2.11 |  |  |  | 8.9 |
Granted |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Outstanding at December 31, 2023 |  |  | 2,074,505 |  |  |  | 8.51 |  |  |  | 2.11 |  |  |  | 7.9 |
Granted |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Outstanding at December 31, 2024 |  |  | 2,074,505 |  |  |  | 8.51 |  |  |  | 2.11 |  |  |  | 6.8 |
Options vested and exercisable at December 31, 2024 |  |  | 1,816,336 |  |  | $ | 8.86 |  |  | $ | 2.14 |  |  |  | 6.8 |
During the years ended December 31, 2024 and 2023, the Company expensed stock based compensation related to stock options of $1.1 million and $1.5 million, respectively, which is included in general and administrative expenses in the Consolidated Statements of Operations. Unrecognized Stock-Based Compensation As of December 31, 2024, the Company had $0.1 million, of unrecognized compensation costs, related to 13,589 outstanding RSUs and 258,169 stock options, expected to be recognized over a weighted average period of less than one year. All RSUs and stock options are expected to vest. Common Stock The Company is authorized to issue up to 37,500,000 shares of Common Stock, $0.001 par value per share. The following table summarizes issuances of shares of our common stock for the years ended December 31, 2024 and 2023 (amounts in thousands):
|  |  | Year Ended December 31, |
Issuance | Additional disclosure |  | 2024 |  |  | 2023 |
Vesting of employee stock awards (1) | Stock-Based Compensation discussion above |  |  | 11,623 |  |  |  | 153,324 |
| (1) | Amounts are net of shares withheld to cover employee tax payments. Amounts vested are for various employees.
Preferred Stock Our Board of Directors has the authority, without stockholder approval, to issue up to 1,000,000 shares of Preferred Stock, $0.001 par value. The authorized Preferred Stock may be issued by the Board of Directors in one or more series and with the rights, privileges and limitations of the Preferred Stock determined by the Board of Directors. The rights, preferences, powers and limitations of different series of Preferred Stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions, and other matters. As of December 31, 2024, we have no Preferred Stock issued or outstanding. Employee 401(k) Plan The Company has established a savings plan ("Savings Plan") which is qualified under Section 401(k) of the Internal Revenue Code. Eligible employees may elect to make contributions to the Savings Plan through salary deferrals of up to 90% of their base pay, subject to Internal Revenue Code limitations. The Company contributes to the Savings Plans, subject to limitations. For the years ended December 31, 2024 and 2023, the Company contributed $327 thousand and $274 thousand, respectively, in matching contributions to the Savings Plan.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration